Antibe Therapeutics Inc. (ATE.TO) Research

Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.

Market snapshot

Symbol
ATE.TO
Price
$0.30
Day change
+13.46%
Market cap
$15.6M
P/E ratio
-0.79x
52-week range
0.15-1.23
Sector
Healthcare
Industry
Medical - Devices

Peer companies

  • Chalice Brands Ltd. (CHAL.CN)
  • EXMceuticals Inc. (EXM.CN)
  • Fire & Flower Holdings Corp. (FAF.TO)
  • IMV Inc. (IMV.TO)
  • LexaGene Holdings Inc. (LXG.V)
  • Marvell Technology, Inc. (MRV.TO)
  • Numinus Wellness Inc. (NUMI.TO)
  • Reunion Neuroscience Inc. (REUN.TO)

Open Antibe Therapeutics Inc. (ATE.TO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.